Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Retained Earnings (2024 - 2025)

Evommune (EVMN) has disclosed Retained Earnings for 2 consecutive years, with -$221.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 45.24% to -$221.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$221.1 million through Dec 2025, down 45.24% year-over-year, with the annual reading at -$221.1 million for FY2025, 45.24% down from the prior year.
  • Retained Earnings for Q4 2025 was -$221.1 million at Evommune, down from -$192.8 million in the prior quarter.
  • The five-year high for Retained Earnings was -$152.2 million in Q4 2024, with the low at -$221.1 million in Q4 2025.